Denmark - Novo Nordisk today announced that the acquisition of Emisphere Technologies Inc. (Emisphere), announced on 6 November 2020, has now been completed.

The adoption of the merger agreement was approved by Emisphere shareholders today, and early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 was granted on 23 November 2020.

About Novo Nordisk

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 44,000 people in 80 countries and markets its products in around 170 countries.

Contact:

Mette Kruse Danielsen

Tel: +45 30 79 38 83

Email: mkd@novonordisk.com

(C) 2020 Electronic News Publishing, source ENP Newswire